Serotonin and the Scientific Basis of Anti-Emetic Therapy,

Abstract

Abstract : Emesis research: a concise history of the critical concepts and experiments; The physiology of emesis induced by anti-cancer therapy; The discovery of selective 5-hydroxytryptamine-3 (5-HT3) receptor antagonists; The clinical approach to chemotherapy-induced emesis; How do toxic emetic stimuli cause 5-HT release in the gut and brain?; The role of free radicals and nitric oxide in the induction of emesis; The pharmacology of 5-HT release from enterochromaffin cells; The vagal afferent response to 5-HT and cisplatin; The electrophysiology of vagal and recombinant 5-HT3 receptors; 5-HT3 receptors in the dorsal vagal complex; Where do 5-HT3 receptor antagonists act as anti-emetics?; 5-HT3 receptor antagonists and radiation-induced emesis: preclinical data; Clinical evidence for 5-HT3 receptor antagonist efficacy in radiation-induced emesis; Clinical evidence for the involvement of serotonin in acute cytotoxic-induced emesis; What is the involvement of 5-HT3 receptors in postoperative nausea and vomiting?; Preclinical differences in 5-HT3 receptor antagonist characteristics; Are there any true clinical differences hetween 5-HT3 receptor antagonists?; Limitations in the efficacy of 5-HT3 receptor antagonists; Does 5-HT play a role in the delayed phase of cisplatin-induced emesis?; 5-HT4 receptor involvement in emesis; Are 5-HT3 receptor effects on gastrointestinal motility relevant to anti-emesis?; Opioid receptor involvement in emesis and anti-emesis